Research programme: rheumatoid arthritis therapies - Selecore
Latest Information Update: 01 Mar 2011
At a glance
- Originator Selecore
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 07 Sep 2005 Preclinical trials in Rheumatoid arthritis in Germany (PO)